KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript [Seeking Alpha]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Seeking Alpha
Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Paul Audhya - Chief Medical Officer Nicole Sweeny - Chief Commercial Officer Brian Piekos - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Stacy Ku - TD Cowen, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to KalVista Pharmaceuticals' 2025 Third Quarter Financial Update and Operating Results Conference Call. [Operator Instructions] Please note that today's conference is being recorded. I will now hand the conference over to your first spea
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]Yahoo! Finance
- KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.MarketBeat
- KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]Yahoo! Finance
KALV
Earnings
- 11/10/25 - Beat
KALV
Sec Filings
- 1/26/26 - Form S-8
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- KALV's page on the SEC website